Take part in a new research study for a potential new treatment for Coeliac Disease.
This study aims to assess the safety and efficacy of the investigational treatment. The trial is open for coeliac disease patients who have persistent symptoms/damage despite maintaining a Gluten Free Diet.
For out-of-pocket expenses, such as travel and parking.
Help investigate a potential new treatment that could improve the lives of individuals with coeliac disease.
Be among the first to access potential new research treatments before they are widely available.
Receive top-tier medical care and monitoring from experienced healthcare professionals.
You may be able to take part if the following apply. Eligibility is confirmed at a free screening visit (other criteria apply).
Unfortunately, if any of the following apply to you, this study is not the right fit for you:
Please note, additional eligibility criteria apply.
If you are deemed eligible for the study, you participation is expected to last approximately 54 weeks, and you will be required to attend the study site up to 15 times. This includes:
*Participation in the study involves gluten exposure approximately 3 times per week (at home) per the guidelines of the study doctor throughout the treatment period. The amount of gluten provided each time is reflective of approximately 1 small bite of white toast.
Participation in this research is voluntary, and you may withdraw from the study at any time.
This study aims to assess the safety and efficacy of the investigational product (DONQ52) in active coeliac disease patients who have persistent symptoms/damage despite attempting to maintain a Gluten Free Diet.
Participants will be asked to partake in a gluten challenge as part of the study and will receive either the investigation product, or a placebo during the treatment window.
Coeliac disease is an autoimmune condition where the ingestion of gluten triggers an immune response that damages the lining of the small intestine. This can lead to malabsorption of nutrients and a variety of digestive and systemic symptoms.
This study is important because it aims to explore potential new treatments for Coeliac Disease, a condition that currently has no cure. By advancing research, it could improve the quality of life for people living with Coeliac disease and offer more effective management options beyond a gluten-free diet.
This study is being sponsored by Chugai Pharmaceuticals, a Japanese pharmaceutical company headquartered in Tokyo, Japan.
Chugai's founding spirit of "Creating drugs that benefit the world" remains firmly rooted as their integral business philosophy "Innovation all for the patients".
We're here for you! Click or tap the button below to read the study FAQs or to send an email to our friendly Patient Experience team:
It takes only a few minutes to see if you, or someone you care for, may be eligible — with no obligation to take part.
Register Now →